3 Global Generics Leader, Specialty Branded Generics Seller and Pain and Anti-Malarial Brand Owner Stocks With a Strong Future Roadmap: Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories
- October 26, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories: ROE of 11.1% to 23.3% and FY22 to FY26 revenue CAGR of 12.3% to 13.6%. Prices as of 23 Oct 2026.
Quick Answer
The three global generic and specialty pharma stocks to watch are Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories. Their return on equity ranges from 11.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.3% to 13.6%. Ajanta Pharma has the highest return on equity at 23.3%, while Ipca Laboratories has the fastest revenue growth at 13.6% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Global generic and specialty pharma stocks bring together companies with a visible plan for the years ahead. Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories cover a global generics leader, a specialty branded generics seller and a pain and anti-malarial brand owner.
This list covers three global generic and specialty pharma stocks with complete current figures: Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Global Generic and Specialty Pharma Stocks?
Global generic and specialty pharma stocks are listed drug makers that sell generics, specialty brands and active ingredients in India, North America and emerging markets. Their earnings depend on launches, approvals, product mix and export demand.
Global Generic and Specialty Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories | 1,229.5 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| Ajanta Pharma | 3,283.9 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| Ipca Laboratories | 1,953.3 | 46,050 | 33.5 | 36.0 | 14.2 | 0.10 |
On valuation, Dr. Reddy’s Laboratories and Ipca Laboratories trade at a P/E below the industry P/E, while Ajanta Pharma trades above it, which reflects the growth the market already expects. Readers comparing global generic and specialty pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Global Generic and Specialty Pharma Stocks Have a Strong Roadmap in India?
Global generic and specialty pharma stocks have a strong roadmap in India because a wide product pipeline, specialty brand strength and growing exports keep widening the revenue base.
- Product pipeline. New launches in regulated markets add revenue.
- Specialty brands. Eye, skin and pain brands earn repeat prescriptions.
- Emerging markets. Branded exports to Asia and Africa add steady orders.
Why Dr. Reddy’s Laboratories Features Among These Global Generic and Specialty Pharma Stocks
Among the global generic and specialty pharma stocks on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why Ajanta Pharma Features Among These Global Generic and Specialty Pharma Stocks
Among the North America generics company shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%.
In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.
Why Ipca Laboratories Features Among These Global Generic and Specialty Pharma Stocks
Among the three companies on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.
In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%.
Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.
Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.
Dr. Reddy’s Laboratories vs Ajanta Pharma vs Ipca Laboratories on Key Financials
The table below sets the three global generic and specialty pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| Ipca Laboratories | 5,896 | 9,821 | 13.6% | 1,191 | 12.1% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. Dr. Reddy’s Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Ipca Laboratories shows the fastest revenue growth with a 13.6% compound annual rate. A useful habit with global generic and specialty pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Global Generic and Specialty Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these global generic and specialty pharma stocks, the main points are: Long-term North America generics company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter global generic and specialty pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Global Generic and Specialty Pharma Stocks
Global generic and specialty pharma stocks suit investors who prefer to study business strength before price moves. Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories each have a clear plan to grow. Based on the 23 October 2026 close, Dr. Reddy’s Laboratories trades at Rs 1,229.5, Ajanta Pharma at Rs 3,283.9 and Ipca Laboratories at Rs 1,953.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these global generic and specialty pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track global generic and specialty pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are global generic and specialty pharma stocks?
Ans. Global generic and specialty pharma stocks are listed drug makers that sell generics, specialty brands and active ingredients in India, North America and emerging markets. Their earnings depend on launches, approvals, product mix and export demand. This list looks at three of them, Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which global generic and specialty pharma stocks are covered in this list?
Ans. This list covers Dr. Reddy’s Laboratories, Ajanta Pharma and Ipca Laboratories. Based on the 23 October 2026 close, Dr. Reddy’s Laboratories traded at Rs 1,229.5, Ajanta Pharma at Rs 3,283.9 and Ipca Laboratories at Rs 1,953.3. Their return on equity ranges from 11.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.3% to 13.6%.
Why do global generic and specialty pharma stocks have a strong future roadmap in India?
Ans. Global generic and specialty pharma stocks have a strong roadmap in India because a wide product pipeline, specialty brand strength and growing exports keep widening the revenue base. The main drivers are as follows. Product pipeline. New launches in regulated markets add revenue. Specialty brands. Eye, skin and pain brands earn repeat prescriptions. Emerging markets. Branded exports to Asia and Africa add steady orders. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has Ipca Laboratories performed financially?
Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What risks should investors check before buying global generic and specialty pharma stocks?
Ans. Investors should check a few risks before buying global generic and specialty pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of global generic and specialty pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
